-
Chapter
Ozone-Induced Bronchial Hyperreactivity
Ozone (03) is a powerful oxidizing agent which is classified as a “secondary air pollutant”. Secondary air pollutants are not emitted into the atmosphere but formed from subsequent atmospheric chemical reactions ...
-
Chapter
Future Trends in the Use of Corticosteroids in Asthma
Corticosteroids have been used to treat a variety of airway diseases since the early 1950s, following an initial study of Carryer et al. [1], who reported the benefits of oral cortisone on ragweed pollen-induc...
-
Article
A GABAergic system in airway epithelium is essential for mucus overproduction in asthma
γ-Aminobutyric acid (GABA) is an important neurotransmitter that, through the subtype A GABA receptor (GABAAR), induces inhibition in the adult brain. Here we show that an excitatory, rather than inhibitory, GABA...
-
Chapter
Mechanisms and Management of Exercise-Induced Bronchoconstriction
The term “exercise-induced asthma” has been used to describe the transient narrowing of the airways and the subsequent increase in airway resistance, which can occur during, though more commonly following, vig...
-
Article
Open AccessFunctional genomics of the peripheral blood response to allergen inhalation challenge
-
Article
Open AccessRoflumilast attenuates allergen-induced inflammation in mild asthmatic subjects
Phosphodiesterase 4 (PDE4) inhibitors increase intracellular cyclic adenosine monophosphate (cAMP), leading to regulation of inflammatory cell functions. Roflumilast is a potent and targeted PDE4 inhibitor. Th...
-
Article
Open AccessOverall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps
Adjusting medication for uncontrolled asthma involves selecting one of several options from the same or a higher treatment step outlined in asthma guidelines. We examined the relative benefit of introducing bu...
-
Article
Open AccessDecreased miR-192 expression in peripheral blood of asthmatic individuals undergoing an allergen inhalation challenge
MicroRNAs are small non-coding RNAs that regulate gene expression at the post-transcriptional level. While they have been implicated in various diseases, the profile changes in allergen inhalation challenge ar...
-
Article
The pharmacological modulation of allergen-induced asthma
Aeroallergens are the most common triggers for the development of asthma. Recent birth cohort studies have identified viral infections occurring against a background of aeroallergen sensitization as a potent r...
-
Article
Open AccessTh17/Treg ratio derived using DNA methylation analysis discriminates allergen-induced early from dual asthmatic responses
-
Article
Open AccessComparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids
Current maintenance therapies for asthma require twice-daily dosing. Vilanterol (VI) is a novel long-acting beta2 agonist, under development in combination with fluticasone furoate, a new inhaled corticosteroid (...
-
Article
Open AccessTh17/Treg ratio derived using DNA methylation analysis is associated with the late phase asthmatic response
The imbalance between Th17 and Treg cells has been studied in various diseases including allergic asthma but their roles have not been fully understood in the development of the late phase asthmatic response.
-
Article
Open AccessEfficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial
Fluticasone furoate (FF) is a novel, once-daily inhaled corticosteroid (ICS) that has been shown to improve lung function vs. placebo in asthma patients. This study evaluated the efficacy and safety of FF 50 m...
-
Article
Open AccessBlood biomarkers of the late phase asthmatic response using RNA-Seq
-
Article
Open AccessDose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study
Olodaterol is a novel, inhaled long-acting β2-agonist (LABA) with >24-h duration of action investigated in asthma and chronic obstructive pulmonary disease.
-
Article
Open AccessProceedings of the Canadian society of allergy and clinical immunology annual scientific meeting 2015
A1 Role of fibrocytes in allergic rhinitis
-
Article
Open AccessIntegrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma
Fluticasone furoate is a once-daily inhaled corticosteroid. This report provides an overview of safety and efficacy data that support the use of once-daily fluticasone furoate 100 μg or 200 μg in adult and ado...
-
Article
Open AccessTherapeutic interventions in severe asthma
The present paper addresses severe asthma which is limited to 5-10% of the overall population of asthmatics. However, it accounts for 50% or more of socials costs of the disease, as it is responsible for hospi...
-
Article
Open AccessAllerGen’s 8th research conference
-
Chapter
Anti-IgE and Biologic Approaches for the Treatment of Asthma
Current asthma treatments are effective for the majority of patients with mild-to-moderate disease. However, in those with more severe refractory asthma, agents other than inhaled corticosteroids and beta-agon...
